Recent Posts on This Topic | See All >
[Sourve: Oncology Nursing News] - Research conducted at The University of Arizona suggests that a drug may be able to change the function of hard-to-treat tumor cells so they will be more responsive to chemotherapy or radiation.
To gain greater response rates on melanoma tumors in cell cultures, Randy Burd, PhD, assistant professor of nutritional sciences and member of The University of Arizona's BIO5 Institute, has been testing dacarbazine, the standard chemotherapeutic drug, along with its analog temozolomide, in combination with various bioactive compounds.
For more information: Tumor-Sensitizing Drugs May Enhance Cancer Therapy
Now available: “Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is now available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” An overview by Walter Plosila, Ph.D., Battelle senior advisor, is also available. The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade.